Alflutinib Mesylate

甲磺酸伏美替尼

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameAlflutinib Mesylate
Drug Alias Name甲磺酸艾氟替尼Furmonertinib伏美替尼firmonertinib mesylate艾弗沙 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitors
TargetsEGFR T790M
Therapy Area/IndicationsPleural Effusion, MalignantCarcinoma, Non-Small-Cell LungAdenocarcinoma of Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2021/03/02
Country/TerritoryCanadaUnited StatesSingapore +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Allist Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Fosun Pharmaceutical (Group) Co LtdJiangmen Central HospitalArriVent Biopharma Inc +[4] 
Inactive CompaniesTongji UniversityFudan UniversitySun Yat-Sen University +[4] 
Active IndicationsPleural Effusion, MalignantCarcinoma, Non-Small-Cell LungAdenocarcinoma of Lung
Inactive IndicationsN/A

Other Information

ATC CodeL01XE
Related LinksN/A